Russian retail animal drugs market is set to cross RUB 18.5 billion (retail prices, including VAT) from January to October 2021. Retail sales of animal drugs fell 6.3% between January-October 2020, experts said. This includes retail sales of drugs in minimum dosage units (MDU).
Totally, since the beginning of 2021, consumers have purchased 144 million of animal drugs at retail level.
Comparing the retail animal drugs market volumes between October 2020-October 2021, the sales volumes in RUB dropped by 0,1% compared to the last year, whereas retail drug sales in minimum dosage units dropped by 8,7%.
“An increase in demand for certain animal drugs last year was evidently triggered by the second wave of Covid-19 pandemic,” explained experts. According to them, this is quite normal for animal drugs market in fall and winter. Animal drugs sales tend to decline by the end of the year, and, particularly, it is obvious in contrast to the peak demand which occurs in spring and fall.
Thus, from January to October 2021 the maximum retail sales volume among foreign producers of animal drugs has been reached by Livisto (+29% in RUB) and Zoetis (+24% in RUB).
“There has been a growth in retail sales of anthelmintic Albendazole (retail sales rose by 5.3 times this year) and nonsteroidal anti-inflammatory drug Petkam (+ 54%) produced by Livisto. Regarding company Zoetis, there has been a growth in retail sales of insectoacaricide Simparica (+39%) and antibacterial drug Synulox (+33%),” commented RNC Pharma.
As to the Russian companies, Agrobioprom reported a 21% growth in the sales of animal drugs between January-October 2021. The company’s top-selling drugs were sedative VetSpokoin (+47%) and ear drops Otidez (+29%), said experts.
